Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 4/2015

22.07.2015 | ORIGINAL ARTICLE

Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

verfasst von: Narendra Hulikal, Sivanath Reddy Gajjala, Teck Chand Kalawat, Radhika Kottu, Lakshmi Amancharla Yadagiri

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

In India up to 50 % of breast cancer patients still present as locally advanced breast cancer (LABC). The conventional methods of metastatic work up include physical examination, bone scan, chest & abdominal imaging, and biochemical tests. It is likely that the conventional staging underestimates the extent of initial spread and there is a need for more sophisticated staging procedure. The PET/CT can detect extra-axillary and occult distant metastases and also aid in predicting response to chemotherapy at an early point in time. To evaluate the utility of FDG PET/CT in initial staging and response assessment of patients with LABC receiving NACT. A prospective study of all biopsy confirmed female patients diagnosed with LABC receiving NACT from April 2013 to May 2014. The conventional work up included serum chemistry, CECT chest and abdomen and bone scan. A baseline whole body PET/CT was done in all patients. A repeat staging evaluation and a whole body PET/CT was done after 2/3rd cycle of NACT in non-responders and after 3/4 cycles in clinical responders. The histopathology report of the operative specimen was used to document the pathological response. The FDG PET/CT reported distant metastases in 11 of 38 patients, where as conventional imaging revealed metastases in only 6. Almost all the distant lesions detected by conventional imaging were detected with PET/CT, which showed additional sites of metastasis in 3 patients. In 2 patients, PET/CT detected osteolytic bone metastasis which were not detected by bone scan. In 5 patients PET CT detected N3 disease which were missed on conventional imaging. A total of 14 patients had second PET/CT done to assess the response to NACT and 11 patients underwent surgery. Two patients had complete pathological response. Of these 1 patient had complete metabolic and morphologic response and other had complete metabolic and partial morphologic response on second PET/CT scan. The 18 FDG PET/CT can detect more number of metastasis as well as additional sites of metastasis compared to conventional methods. The response assessment resulted in change of treatment regimen in 14 % of patients.
Literatur
2.
Zurück zum Zitat AJCC (American Joint Committee on Cancer) (2010) In: Edge SB, Byrd DR, Compton CC et al (eds) Cancer staging manual, 7th edn. Springer, New York, p 347CrossRef AJCC (American Joint Committee on Cancer) (2010) In: Edge SB, Byrd DR, Compton CC et al (eds) Cancer staging manual, 7th edn. Springer, New York, p 347CrossRef
3.
Zurück zum Zitat Tham YL, Kramer R, Osborne CK (2010) Evaluation of patients for metastasis prior to primary therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 4th edn. Lippincott Williams & Wilkins, Philadelphia, p 483 Tham YL, Kramer R, Osborne CK (2010) Evaluation of patients for metastasis prior to primary therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 4th edn. Lippincott Williams & Wilkins, Philadelphia, p 483
4.
Zurück zum Zitat Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N et al (2008) Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19:1249–1254CrossRefPubMed Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N et al (2008) Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19:1249–1254CrossRefPubMed
5.
Zurück zum Zitat Al-Husaini H, Amir E, Fitzgerald B, Wright F, Dent R, Fralick J et al (2008) Prevalence of overt metastases in locally advanced breast cancer. Clin Oncol (R Coll Radiol) 20(5):340–344CrossRef Al-Husaini H, Amir E, Fitzgerald B, Wright F, Dent R, Fralick J et al (2008) Prevalence of overt metastases in locally advanced breast cancer. Clin Oncol (R Coll Radiol) 20(5):340–344CrossRef
6.
Zurück zum Zitat Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K et al (2001) Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351–358CrossRefPubMed Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K et al (2001) Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351–358CrossRefPubMed
7.
Zurück zum Zitat Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E et al (2008) Effect of (18) F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71:695–704CrossRefPubMed Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E et al (2008) Effect of (18) F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71:695–704CrossRefPubMed
8.
Zurück zum Zitat Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G et al (2008) Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751CrossRefPubMed Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G et al (2008) Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751CrossRefPubMed
9.
Zurück zum Zitat Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, Van Geldere D et al (2004) 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 22:1253–1259CrossRefPubMed Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, Van Geldere D et al (2004) 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 22:1253–1259CrossRefPubMed
10.
Zurück zum Zitat Von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, German Breast Group et al (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30CrossRef Von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, German Breast Group et al (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30CrossRef
11.
Zurück zum Zitat De Boer RH, Saini A, Johnston SR, O’Brien ME, Ellis PA, Verrill MW et al (2000) Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. Breast 9:149–155CrossRefPubMed De Boer RH, Saini A, Johnston SR, O’Brien ME, Ellis PA, Verrill MW et al (2000) Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. Breast 9:149–155CrossRefPubMed
12.
Zurück zum Zitat Auclerc G, Borel C, Khayat D, Soubrane C (1992) Weil M [Primary chemotherapy in the treatment of breast cancer]. Ann Chir Plast Esthet 37:663–669PubMed Auclerc G, Borel C, Khayat D, Soubrane C (1992) Weil M [Primary chemotherapy in the treatment of breast cancer]. Ann Chir Plast Esthet 37:663–669PubMed
13.
Zurück zum Zitat Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18. Cancer 95:681–695CrossRefPubMed Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18. Cancer 95:681–695CrossRefPubMed
14.
Zurück zum Zitat Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19:4224–4237PubMed Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19:4224–4237PubMed
15.
Zurück zum Zitat Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan cancer institute. J Clin Oncol 16:93–100PubMed Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan cancer institute. J Clin Oncol 16:93–100PubMed
16.
Zurück zum Zitat Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578–2581PubMed Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578–2581PubMed
17.
Zurück zum Zitat NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 3.2014. National Comprehensive Cancer Network. Available at http://bit.ly/jOuSUf. Accessed October 2, 2014. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 3.2014. National Comprehensive Cancer Network. Available at http://​bit.​ly/​jOuSUf. Accessed October 2, 2014.
18.
Zurück zum Zitat Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C et al (2013) 18F FDG PET/CT in patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 54:5–11CrossRefPubMed Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C et al (2013) 18F FDG PET/CT in patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 54:5–11CrossRefPubMed
19.
Zurück zum Zitat Wolfgang A (2009) Weber. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46:963–995 Wolfgang A (2009) Weber. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46:963–995
20.
Zurück zum Zitat Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemotherapy using positron emission tomography-initial evaluation. J Clin Oncol 11:2101–2111PubMed Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemotherapy using positron emission tomography-initial evaluation. J Clin Oncol 11:2101–2111PubMed
21.
Zurück zum Zitat Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D et al (2000) Positron emission tomography using [(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689–1695PubMed Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D et al (2000) Positron emission tomography using [(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689–1695PubMed
22.
Zurück zum Zitat Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F et al (2000) Positron emission tomography using [(18) F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676–1688PubMed Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F et al (2000) Positron emission tomography using [(18) F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676–1688PubMed
23.
Zurück zum Zitat Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366–5372CrossRefPubMed Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366–5372CrossRefPubMed
24.
Zurück zum Zitat McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI et al (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102:75–84CrossRefPubMed McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI et al (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102:75–84CrossRefPubMed
25.
Zurück zum Zitat Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose. J Clin Oncol 27:535–541CrossRefPubMed Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose. J Clin Oncol 27:535–541CrossRefPubMed
26.
Zurück zum Zitat Dunnwald LK, Gralow JR, Ellis GK (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457CrossRefPubMedPubMedCentral Dunnwald LK, Gralow JR, Ellis GK (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Groheux D, Hindie E, Giacchetti S, Delord M, Hamy AS, Roquancourt AD et al (2012) Triple negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at high risk of early relapse. J Nucl Med 53:249–254CrossRefPubMed Groheux D, Hindie E, Giacchetti S, Delord M, Hamy AS, Roquancourt AD et al (2012) Triple negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at high risk of early relapse. J Nucl Med 53:249–254CrossRefPubMed
28.
Zurück zum Zitat Skoura EV, Datseris IE (2007) PET imaging in breast cancer. Hosp Chronicles 2:12–18 Skoura EV, Datseris IE (2007) PET imaging in breast cancer. Hosp Chronicles 2:12–18
Metadaten
Titel
Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
verfasst von
Narendra Hulikal
Sivanath Reddy Gajjala
Teck Chand Kalawat
Radhika Kottu
Lakshmi Amancharla Yadagiri
Publikationsdatum
22.07.2015
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 4/2015
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-015-0421-0

Weitere Artikel der Ausgabe 4/2015

Indian Journal of Surgical Oncology 4/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.